{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:01:24Z","timestamp":1764954084799,"version":"3.46.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejpb.2025.114911","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:02:18Z","timestamp":1762038138000},"page":"114911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Analysis of discrepancy in SNEDDS performance for a \u201cbrick dust\u201d mebendazole between in-vitro and in-vivo estimation"],"prefix":"10.1016","volume":"218","author":[{"given":"Seito","family":"Maehara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-2813","authenticated-orcid":false,"given":"Masato","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-8575","authenticated-orcid":false,"given":"Kazutaka","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114911_b0005","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/03639045.2017.1342654","article-title":"Review and analysis of FDA approved drugs using lipid-based formulations","volume":"43","author":"Savla","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106556","article-title":"Lipid based formulations as supersaturating oral delivery systems: from current to future industrial applications","volume":"189","author":"Holm","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114911_b0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sinica B"},{"key":"10.1016\/j.ejpb.2025.114911_b0020","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1021\/mp500790t","article-title":"Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations","volume":"12","author":"Sahbaz","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11095-019-2590-y","article-title":"New insights into using lipid based suspensions for \u2018brick dust\u2019 molecules: case study of nilotinib","volume":"36","author":"Koehl","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114911_b0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jphp.12984","article-title":"Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches \u2013 PEARRL review","volume":"71","author":"Ditzinger","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114911_b0035","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.addr.2007.05.013","article-title":"Prodrug strategies to overcome poor water solubility","volume":"59","author":"Stella","year":"2007","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ejpb.2025.114911_b0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.addr.2016.02.005","article-title":"Computational prediction of formulation strategies for beyond-rule-of-5 compounds","volume":"101","author":"Bergstr\u00f6m","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2025.114911_b0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/open.201600015","article-title":"Melting point distribution analysis of globally approved and discontinued drugs: a research for improving the chances of success of drug design and discovery","volume":"5","author":"Mao","year":"2016","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.ejpb.2025.114911_b0050","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/js980403l","article-title":"Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs","volume":"88","author":"Serajuddin","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114911_b0055","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1021\/acs.chemrev.6b00562","article-title":"Biological activity of ionic liquids and their application in pharmaceutics and medicine","volume":"117","author":"Egorova","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejpb.2025.114911_b0060","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejpb.2017.04.021","article-title":"Lipophilic salts of poorly soluble compounds to enable high-dose lipidic SEDDS formulations in drug discovery","volume":"117","author":"Morgen","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejpb.2018.05.028","article-title":"Nanocrystal-silica-lipid hybrid particles for the improved oral delivery of ziprasidone in vitro","volume":"129","author":"Meola","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0070","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijpharm.2018.12.036","article-title":"Co-former selection for co-amorphous drug-amino acid formations","volume":"557","author":"Kasten","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0075","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejpb.2020.11.004","article-title":"Physical formulation approaches for improving aqueous solubility and bioavailability of ellagic acid: a review","volume":"159","author":"Nyamba","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/pharmaceutics15010084","article-title":"Formation of a stable co-amorphous system for a brick dust molecule by utilizing sodium taurocholate with high glass transition temperature","volume":"15","author":"Aikawa","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114911_b0085","first-page":"2503","article-title":"Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach, Drug deliv","volume":"13","author":"Chougule","year":"2023","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejpb.2025.114911_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114241","article-title":"Supersaturable diacyl phospholipid dispersion for improving oral bioavailability of brick dust molecule: a case study of aprepitant","volume":"197","author":"Lale","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2022.06.057","article-title":"Combining lipid based drug delivery and amorphous solid dispersions for improved oral drug absorption of poorly water-soluble drug","volume":"349","author":"Nora","year":"2022","journal-title":"J. Controlled Rel."},{"key":"10.1016\/j.ejpb.2025.114911_b0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12249-024-02780-3","article-title":"Utilization of lipophilic salt and phospholipid complex in lipid-based formulations modulate drug loading and oral bioavailability of pazopanib","volume":"25","author":"Jadhav","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2025.114911_b0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.biopha.2004.02.001","article-title":"Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs","volume":"58","author":"Gursoy","year":"2004","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2025.114911_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1018987928936","article-title":"Self-emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound","volume":"9","author":"Charman","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114911_b0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0378-5173(94)90271-2","article-title":"Selfemulsifying drug delivery systems (SEDDS) with polyglycolysed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs","volume":"106","author":"Shah","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2013.02.005","article-title":"Proposal of stability categories for nano-dispersions obtained from pharmaceutical self-emulsifying formulations","volume":"446","author":"Niederquell","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105721","article-title":"Improvement of lipid solubility and oral bioavailability of a poorly water-soluble and poorly lipid-soluble drug, rebamipide, by utilizing its counter ion and SNEDDS preparation","volume":"159","author":"Okawa","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114911_b0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejpb.2022.02.002","article-title":"Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ion","volume":"172","author":"Sumimoto","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124197","article-title":"Combination of co-amorphization with SNEDDS outperforms Ofev\u00ae in the oral absorption of nintedanib","volume":"657","author":"Inoue","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejps.2004.10.005","article-title":"Clinical study of solid dispersions of itraconazole prepared by hotstage extrusion","volume":"24","author":"Six","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114911_b0145","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersatrurating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114911_b0150","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics12040365","article-title":"Current status of supersaturable self-emulsifying drug delivery systems","volume":"12","author":"Park","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114911_b0155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.2042-7158.1991.tb06697.x","article-title":"Intestinal absorption of drugs. the influence of mixed micelles on the disappearance kinetics of drugs from the small intestine of the rat","volume":"43","author":"Poelma","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114911_b0160","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1023\/A:1023481418576","article-title":"Human Jejunal permeability of cyclosporin a: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells","volume":"20","author":"Chiu","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114911_b0165","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/jps.10511","article-title":"Development of supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability","volume":"92","author":"Gao","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114911_b0170","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1002\/jps.22033","article-title":"The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone","volume":"99","author":"Dahan","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114911_b0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2013.03.054","article-title":"Lipid-based formulations for oral administration of poorly water-soluble drugs","volume":"453","author":"Mu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0180","first-page":"443","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Repurposing Drugs in Oncology (ReDO)\u2014Mebendazole as an Anti-Cancer Agent."},{"key":"10.1016\/j.ejpb.2025.114911_b0185","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00436-012-2954-2","article-title":"Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus","volume":"111","author":"Liu","year":"2012","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejpb.2025.114911_b0190","first-page":"117","article-title":"Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences","volume":"58","author":"Swanepoel","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2025.114911_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125458","article-title":"Dynamic changes in the distribution equilibrium of drugs in microemulsions associated with drug absorption facilitate the absorption improvement for drugs with low water-solubility by self-microemulsifying drug delivery system (SMEDDS)","volume":"674","author":"Nishiyama","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.60.1.0008","article-title":"Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments","volume":"60","author":"McConnell","year":"2008","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114911_b0205","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2007.03.002","article-title":"Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study","volume":"119","author":"Fujioka","year":"2007","journal-title":"J. Controlled Rel."},{"key":"10.1016\/j.ejpb.2025.114911_b0210","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1248\/bpb1978.4.879","article-title":"A pharmacokinetic analysis program (MULTI) for microcomputer","volume":"4","author":"Yamaoka","year":"1981","journal-title":"J. Pharmacobio-Dyn."},{"key":"10.1016\/j.ejpb.2025.114911_b0215","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2011.07.045","article-title":"Solvent shift method for anti-precipitant screening of poorly soluble drugs using biorelevant medium and dimethyl sulfoxide","volume":"419","author":"Yamashita","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"2013","key":"10.1016\/j.ejpb.2025.114911_b0220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpharm.2013.05.013","article-title":"Drug precipitation inhibitors in supersaturable formulations","volume":"453","author":"Xu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0225","unstructured":"Home page of Shin-Etsu Chemical Co., Ltd. https:\/\/www.metolose.jp\/en\/ pharmaceutical\/."},{"key":"10.1016\/j.ejpb.2025.114911_b0230","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijpharm.2018.02.043","article-title":"Formulation of a poorly water-soluble drugs in sustained-release hollow granules with a high viscosity water-soluble polymer using a fluidized bed rotor granulator","volume":"541","author":"Asada","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0235","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1007\/s11095-013-1126-0","article-title":"Lipid-based formulations and drug supersaturation: Harnessing the unique benefits of the lipid digestion\/absorption pathway","volume":"30","author":"Williams","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114911_b0240","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/jps.23826","article-title":"Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs","volume":"103","author":"Raina","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114911_b0245","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1021\/acs.molpharmaceut.8b01117","article-title":"Insight into amorphous solid dispersion performance by coupled dissolution and membrane mass transfer measurements","volume":"16","author":"Hate","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0250","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1021\/acs.molpharmaceut.9b00956","article-title":"Interplay of supersaturation and solubilization: lack of correlation between concentration-based supersaturation measurements and membrane transport rates in simulated and aspirated human fluids","volume":"16","author":"Elkhabaz","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114911_b0255","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2133\/dmpk.21.45","article-title":"The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type o\/w microemulsion III: the permeation mechanism of a poorly water soluble drug entrapped o\/w microemulsion in rat isolated intestinal membrane by the Ussing chamber method","volume":"21","author":"Araya","year":"2006","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2025.114911_b0260","unstructured":"N.W. Weisbrodt: Motility of the small intestine. In. L.R. Johnson (Ed.), Gastrointestinal Physiology, St. Louis, Mosby, St. Louis, 1997, pp.43-50."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125002887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125002887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:56:31Z","timestamp":1764953791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125002887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S0939641125002887"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114911","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of discrepancy in SNEDDS performance for a \u201cbrick dust\u201d mebendazole between in-vitro and in-vivo estimation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114911"}}